Recent trends in praziquantel nanoformulations for helminthiasis treatment

Author(s)

Mengarda, Ana C. ; Iles, Bruno ; F. Longo, Joao Paulo ; de Moraes, Josue

• Document type: Journal article
• Source: Expert Opinion on Drug Delivery; v. 19, n. 4, p. 11-pg., 2022-03-17.

Abstract

Introduction Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues. Areas covered This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described. Expert opinion Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability. (AU)

• FAPESP's process: 19/25905-2 - Preclinical evaluation for oral administration of nanostructured formulations containing drugs with anthelmintic activity
• Grantee: Ana Carolina Araujo Mengarda
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 20/01441-4 - Drug selection with anthelmintic properties, nanoencapsulation and preclinical evaluation in experimental model of schistosomiasis
• Grantee: Josué de Moraes
• Support Opportunities: Regular Research Grants